# A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

> **NCT06504394** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 66 (estimated)

## Conditions studied

- Classical Hodgkin Lymphoma Recurrent
- Classical Hodgkin Lymphoma Refractory
- Primary Mediastinal Large B-cell Lymphoma Recurrent
- Primary Mediastinal Large B-cell Lymphoma Refractory

## Interventions

- **BIOLOGICAL:** Pembrolizumab (+) Berahyaluronidase alfa

## Key facts

- **NCT ID:** NCT06504394
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-14
- **Primary completion:** 2028-11-08
- **Final completion:** 2028-11-08
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06504394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06504394, "A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06504394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*